|Values are valid only on day of printing.|
Identifying individuals who are at increased risk of adverse drug reactions with drugs that are metabolized by UGT1A1; especially irinotecan, but also including nilotinib, pazopanib, and belinostat
Identifying individuals with Gilbert syndrome due to the presence of homozygous TA7, homozygous TA8, or compound heterozygous TA7/TA8
Identifying individuals who are carriers of Gilbert syndrome due to the presence of heterozygous TA7 or TA8
This genetic test interrogates the thymine-adenine (TA) repeat in the TATA-box of the promoter region of UGT1A1. Repeat number may vary from 5 to 8 TA repeats, with 6 TA repeats representing the most common (normal) number of repeats. Individuals with greater than 6 TA repeats may have an increased risk for adverse drug reactions to drugs metabolized by UGT1A1, especially irinotecan, nilotinib, pazopanib, and belinostat. Homozygosity for TA7, TA8, or compound heterozygosity for TA7/TA8 is also consistent with a diagnosis of Gilbert syndrome. Heterozygosity for TA7 or TA8 is consistent with carrier status for Gilbert syndrome.
See UGT1A1 Test-Ordering Algorithm in Special Instructions.
Polymerase Chain Reaction (PCR) with Fragment Analysis by Capillary Gel Electrophoresis
(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)